Avenue Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	4.64	4.18	5.35	2.48	2.35	Upgrade
Research & Development	6.65	10.36	2.7	1.25	2.87	Upgrade
Operating Expenses	11.28	14.54	8.04	3.74	5.21	Upgrade
Operating Income	-11.28	-14.54	-8.04	-3.74	-5.21	Upgrade
Interest & Investment Income	0.18	0.13	0.02	0.01	0.06	Upgrade
Other Non Operating Income (Expenses)	-0.59	3.93	4.42	-	-	Upgrade
EBT Excluding Unusual Items	-11.7	-10.49	-3.6	-3.73	-5.15	Upgrade
Pretax Income	-11.7	-10.49	-3.6	-3.73	-5.15	Upgrade
Earnings From Continuing Operations	-11.7	-10.49	-3.6	-3.73	-5.15	Upgrade
Minority Interest in Earnings	0.04	0.11	0.05	-	-	Upgrade
Net Income	-11.65	-10.38	-3.55	-3.73	-5.15	Upgrade
Net Income to Common	-11.65	-10.38	-3.55	-3.73	-5.15	Upgrade
Shares Outstanding (Basic)	1	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	1	0	0	0	0	Upgrade
Shares Change (YoY)	817.14%	384.72%	92.83%	2.98%	4.99%	Upgrade
EPS (Basic)	-9.00	-73.48	-121.92	-246.94	-351.08	Upgrade
EPS (Diluted)	-9.00	-73.48	-121.92	-246.94	-351.08	Upgrade
EBIT	-11.28	-14.54	-8.04	-3.74	-5.21	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.